RGEN
Repligen CorporationNASDAQHEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES
Key Statistics
Market Cap
$6.49B
P/E Ratio
126.44
EPS
$0.91
Beta
1.09
52W High
$175.77
52W Low
$100.99
50-Day MA
$117.81
200-Day MA
$137.73
Dividend Yield
—
Profit Margin
6.73%
Forward P/E
58.14
PEG Ratio
1.82
About Repligen Corporation
Repligen Corporation develops and markets bioprocessing systems and technologies for use in the biologic drug manufacturing process in North America, Europe, Asia Pacific, and internationally. The company is headquartered in Waltham, Massachusetts.
Fundamentals
| Revenue (TTM) | $763.34M |
| Gross Profit (TTM) | $405.63M |
| EBITDA | $134.24M |
| Operating Margin | 8.90% |
| Return on Equity | 2.51% |
| Return on Assets | 1.18% |
| Revenue/Share (TTM) | $13.56 |
| Book Value | $37.33 |
| Price-to-Book | 3.08 |
| Price-to-Sales (TTM) | 8.50 |
| EV/Revenue | 8.38 |
| EV/EBITDA | 36.27 |
| Quarterly Earnings Growth (YoY) | 47.90% |
| Quarterly Revenue Growth (YoY) | 14.80% |
| Shares Outstanding | $56.41M |
| Float | $53.37M |
| % Insiders | 5.25% |
| % Institutions | 119.46% |
Historical Volatility
HV 10-Day
57.40%
HV 20-Day
51.76%
HV 30-Day
59.09%
HV 60-Day
52.07%
HV Rank
98.8%
Volatility is currently contracting
Analyst Ratings
Consensus ($178.74 target)
3
Strong Buy14
Buy4
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026